MedCon Highlights a Growing Industry Consensus: Software Defects Need Better Governance, Not Just Faster Fixes
FDA and industry experts are talking more openly about how to manage software defects and anomalies in medical devices. The conversation reflects a broader shift from treating bugs as isolated technical issues to seeing them as governance and quality-system problems.
The MedCon discussion about software defects and anomalies in medical devices captures an important change in tone across medtech. The industry is moving away from the idea that software issues are just engineering glitches and toward a recognition that they are fundamentally governance challenges.
That shift matters because medical software now sits inside increasingly complex systems of updates, integrations, user behavior, and post-market obligations. A defect is not only a line of code problem; it can be a documentation issue, a validation issue, a quality-system issue, or a communication issue between vendor and customer.
The best practices conversation suggests the field is trying to mature faster than the old device model allows. AI and software-enabled products can evolve quickly, but the institutions around them still depend on slower processes built for more stable hardware. Bridging that gap requires better incident reporting, clearer escalation paths, and more disciplined lifecycle management.
For hospitals and manufacturers, this is more than compliance theater. Governance determines whether defects are caught early, whether customers trust fixes, and whether regulatory actions become isolated events or recurring patterns. In a software-driven medtech market, defect management is becoming a core capability, not a back-office function.